Approaches of dengue control: vaccine strategies and future aspects

Runa Akter, Faria Tasneem, Shuvo Das, Mahfuza Afroz Soma, Ilias Georgakopoulos-Soares, Rifat Tasnim Juthi, Saiful Arefeen Sazed

Research output: Contribution to journalReview articlepeer-review

Abstract

Dengue, caused by the dengue virus (DENV), affects millions of people worldwide every year. This virus has two distinct life cycles, one in the human and another in the mosquito, and both cycles are crucial to be controlled. To control the vector of DENV, the mosquito Aedes aegypti, scientists employed many techniques, which were later proved ineffective and harmful in many ways. Consequently, the attention shifted to the development of a vaccine; researchers have targeted the E protein, a surface protein of the virus and the NS1 protein, an extracellular protein. There are several types of vaccines developed so far, such as live attenuated vaccines, recombinant subunit vaccines, inactivated virus vaccines, viral vectored vaccines, DNA vaccines, and mRNA vaccines. Along with these, scientists are exploring new strategies of developing improved version of the vaccine by employing recombinant DNA plasmid against NS1 and also aiming to prevent the infection by blocking the DENV life cycle inside the mosquitoes. Here, we discussed the aspects of research in the field of vaccines until now and identified some prospects for future vaccine developments.

Original languageEnglish (US)
Article number1362780
JournalFrontiers in immunology
Volume15
DOIs
StatePublished - 2024

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this